US EditionPfizer in $41.5 million settlement with Texas over ADHD drug for children
Pfizer and Tris Pharma will pay $41.5 million after Texas alleged they manipulated testing to keep ADHD drug Quillivant XR eligible for Medicaid despite quality issues.
- Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas on Wednesday to resolve a November 2023 lawsuit alleging manipulated testing for Quillivant XR between 2012 and 2018.
- A whistleblower complaint by Tarik Ahmed prompted the suit alleging altered testing methods between 2012 and 2018 so Quillivant XR would meet regulatory requirements, with NextWave Pharmaceuticals developing the drug.
- Pfizer denied wrongdoing and said its review did not find any impact on Quillivant XR’s safety, while Texas Attorney General Ken Paxton said tests showed the liquid often failed to dissolve and violated the Texas Health Care Program Fraud Prevention Act.
- Paxton framed the settlement as enforcement of fraud laws, saying `Under my watch, Big Pharma will not escape justice for lying about the effectiveness of its drugs,` as he campaigns for the 2026 U.S. Senate race.
- The settlement raises questions about Medicaid oversight and enforcement under state law; Tris Pharma manufactured Quillivant for Pfizer until 2018 and requests for comment were not immediately answered.
8 Articles
8 Articles
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over ADHD Drug
Texas Attorney General Ken Paxton on Nov. 19 announced that his office had reached a $41.5 million settlement with Pfizer and Tris Pharma to resolve a November 2023 lawsuit regarding the companies’ distribution of the attention deficit/hyperactivity disorder (ADHD) medication Quillivant to children. Paxton sued the pharmaceutical companies and Tris Pharma CEO Ketan Mehta, alleging that they knowingly provided adulterated Quillivant XR to Texas c…
Pfizer, Tris Pharma Settle For $41.5 Mn In Texas ADHD Drug Case
Texas's top prosecutor on Wednesday announced the state had reached a $41.5 million settlement with US drugmakers Pfizer and Tris Pharma, over allegations of drug adulteration and defrauding the state's Medicaid program.
Pfizer and Tris agree to $41.5 million settlement with Texas over ADHD drug for children
Pfizer and Tris Pharma have agreed to pay $41.5 million to settle allegations by Texas Attorney General Ken Paxton that they provided an ADHD medicine to children on Medicaid while knowing about “flawed” manufacturing practices. The companies were accused of altering testing methods between 2012 and 2018 to ensure the drug, known as Quillivant XR, satisfied regulatory hurdles, according to a lawsuit that was filed two years ago. In doing so, the…
Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit
Pfizer Inc. and Tris Pharma Inc. will pay the state of Texas $41.5 million to settle claims that it allegedly provided adulterated drugs to treat minors for attention-deficit/hyperactivity disorder, Texas Attorney General Ken Paxton (R) announced Wednesday.
Pfizer in $41.5 million settlement with Texas over ADHD drug for children
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded the state's Medicaid program over alleged quality control lapses in a medicine to treat attention deficit hyperactivity disorder in children.
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
